

Lymphoma therapy could deliver a double punch

April 30 2012

B cell lymphomas are a group of cancers of that originate in lymphoid tissue from B cells, the specialized immune cell type that produces antibodies. The development of B cell lymphoma is associated with several known genetic changes, including increased expression of MYC, a transcription factor that promotes cell growth and division.

In this issue of the *JCI*, Andrei Thomas-Tikhonenko and his colleagues at the University of Pennsylvania in Philadelphia report on their studies to better understand the [molecular pathways](#) that interact with MYC and contribute to [B cell lymphoma](#) development. Using a mouse model of lymphoma, they found that a transcription factor in B cells known as PAX5 controls the level of MYC in cells. They showed that PAX5 stabilizes MYC protein levels through a previously undescribed pathway involving CD19, a [surface protein](#) expressed on [B cells](#). When the research team looked in patient samples, they found that high levels of CD19 correlated with high MYC activity, and that both predicted poor patient survival time.

Their findings uncover a CD19-dependent pathway that contributes to the cancerous growth of B cell lymphomas. Their work has direct implications for therapies targeting CD19 that are currently in clinical trials, and suggest that these therapies may reduce cancer-promoting signaling in addition to depleting total B cell numbers.

Provided by Journal of Clinical Investigation

Citation: Lymphoma therapy could deliver a double punch (2012, April 30) retrieved 23 April 2024 from <https://medicalxpress.com/news/2012-04-lymphoma-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.